Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
BioWorld18h
Ultromics’ AI software for cardiac amyloidosis gets FDA approval
Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software that helps with the early diagnosis of cardiac amyloidosis, enabling timely ...
New Hampshire Union Leader15d
Mayo Clinic Q and A: What is cardiac amyloidosis?
My dad was diagnosed with cardiac amyloidosis shortly after his 70th birthday. It’s difficult to pronounce let alone understand. What is cardiac amyloidosis? Am I at risk ...
snmjournals.org11d
Reply to “SPECT Views for Cardiac Amyloidosis Imaging”
REPLY: Thank you for your eagle-eyed attention to detail and for bringing the inconsistency to our attention regarding the SPECT reconstruction display between 2 articles published in the June 2023 ...